Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
November 2, 2023 11:11 AM EDTCiti analyst Andrew Baum said in a note Thursday that the Mounjaro beat for Eli Lilly & Co. (NYSE: LLY) goes on after the companys solid third-quarter results, which were boosted by the drug.
Baum reiterated a Buy rating and $675 price... More
